CD27 and B-cell non-Hodgkin lymphoma: To ensure that the therapeutic benefit of anti-CD20/CD27 therapy was not confined to the BCL1 model, the combination was also tested in the A31 B cell lymphoma (Cobb et al., 1986) (Figure 2B) and Eμ-TCL1, B-chronic lymphocytic leukemia (Bichi et al., 2002) models (Figures 2C–2E).